NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

OKYO Pharma Limited (OKYO) Stock Analysis

OKYO Pharma Limited (OKYO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

OKYO

$1.54

+$0.17 (+12.41%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OKYO with… →

OKYO Key Statistics

As of Oct 21, 2026
Trading
Open
$1.48
Previous Close
$1.37
Day's Range
1.43–1.65
52-Week Range
1.27–3.20
Volume
240.66K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.06
Valuation
Market Cap
$80.82M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.24
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.95M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
52.48M
1-Year Return
−33.62%
Dividend and dates
Avg Volume
72.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OKYO closed at $1.54, −33.62% over 1 year.

OKYO Pharma Limited (OKYO) has a market capitalization of $80.82M.

In fiscal 2025, OKYO reported revenue of $0.00.

OKYO Stock Return by Calendar Year

OKYO Pharma Limited (OKYO) return since May 2022: what $10,000 became

1 year
$10,000 $6,638
−33.62%
3 years
$10,000 $9,686
−3.14%
Since May 2022
$10,000 $4,254
−57.46%

If you had invested $10,000 in OKYO Pharma Limited (OKYO) at the close on May 17, 2022, the earliest close on record here, it would have been worth $4,254 at the close on October 21, 2026: −57.46% in total, −17.55% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−25.60%
2025+80.00%
2024−35.03%
2023−7.33%
2022 (partial year)−47.24%

As of October 21, 2026.

OKYO Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.95M—
2024$0.00−$4.71M—
2023$0.00−$16.83M—
2022$0.00−$13.27M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$8.50M−$8.95M—
2024$0.00—−$7.09M−$4.71M—
2023$0.00—−$15.75M−$16.83M—
2022$0.00—−$13.19M−$13.27M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

OKYO Pharma Limited (OKYO) is capitalised at $80.82M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 5 employees.

The most recent close on file for OKYO is $1.54, dated October 21, 2026. That is +$0.17 (+12.41%) against the previous close. The 52-week range on file runs from $1.27 to $3.20. The latest close sits 21.74% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $8.95M. Trailing earnings per share are −0.24.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −0.06. Annualized volatility over the trailing 4 years is 102.38%. The trailing one-year total return is −33.62%. Across 3 years the annualized return works out at −1.06%.

Growth & Income

The record shows no dividend for OKYO.

The strongest complete calendar year on file is 2025 at +80.00%; the weakest is 2024 at −35.03%. Of the 3 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −25.60% year to date.

Peer Comparison

OKYO Pharma Limited (OKYO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
OKYO Pharma Limited OKYO $80.82M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. OKYO Pharma Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About OKYO Pharma Limited

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Visit website →